Nephera, a Misgav, Israel-based medical device company that was established in the Misgav Venture Accelerator in 2008, completed its $2.85m second round of funding.
Investors include Aurum Ventures, Evergreen Venture Partners, and the Trendlines Group (through its Misgav Venture Accelerator unit).
The new capital will allow the company to launch clinical trials of its device for the treatment of patients suffering from congestive heart failure (CHF). The device, designed to improve and maintain kidney function during these patients’ frequent hospitalizations, is based on electrical stimulation of the urinary system.
Nephera completed a round of pre-clinical trials recently and is expected to begin clinical trials in the coming months.